This webinar was kindly moderated by Donna van Dommelen (Catalyze) and brought together three speakers to talk about MetrioPharm’s lead compound MP1032, a host-directed broad-spectrum anti-infective agent. The webinar was part of the EU-funded iMPact project (https://covidimpact.eu/).
The webinar starts with a presentation by Dr. Wolfgang Brysch (MetrioPharm AG), about the significance of ho...
MetrioPharm has released its annual report 2021. The company has provided an overview of the previous year’s achievements, the current state, and gives an outlook on the future business strategy. Thomas Christély, MetrioPharm’s CEO since last October, mentions in his preface that the company was able to increase its equity by a total of CHF 27.5 million in 2021.
MetrioPharm is currently preparing a clinical trial of its lead compound MP1032 in COVID-19. How do you conduct study preparations under pandemic conditions?
The landscape has changed...
Which are the factors that determine the course of a Covid-19 infection? Whether patients develop symptoms, whether they fall seriously ill, whether they need to be treated in a hospital?
A decisive factor seems to be the age of the patient...
Is MetrioPharm developing a compound for the treatment of COVID-19?
Wolfgang Brysch: We are developing our lead compound MP1032 for the treatment of chronic inflammatory diseases, with the molecule targeting oxidative stress. Oxidative stress also plays a central role in COVID-19 disease...
MetrioPharm recently completed a study in a new preclinical model. What did this model look like?
Dr. Sara Schumann: For this initial study we chose an ex vivo model, in which the tests are performed on an isolated heart and lung system...
MetrioPharm AG has just published Top Line Data for the Phase II clinical trial in psoriasis. Was the study a success?
Wolfgang Brysch: Yes, the study was clearly a success. We had a number of specific questions and were able to answer most of them...
Timetables on the office walls, e-mails with long to-do lists and meetings of all project groups: The new year has started off busy. In order to move the MetrioPharm pipeline ahead as planned, the team is coordinating several major projects simultaneously.
One of the most important is the completion of the Phase II trial in the indication psoriasis...
© MetrioPharm AG 2019
